Quantum dot ligand, preparation method and quantum dot light-emitting device are provided. The quantum dot ligand has a structural general formula as shown in Formula I, XYZ Formula I; wherein X is a coordination group for forming a coordination bond with a quantum dot body; Z is a dissolving group, and the dissolving group is selected from a polar group; Y includes a linking group and a photosensitive group connected with each other, and the linking group is connected between the coordination group and the photosensitive group; the linking group is selected from an alkylene group; the photosensitive group is capable of undergoing bond breaking under light condition such that the quantum dot ligand decomposes into a first unit including the coordination group and the linking group, and a second unit including the dissolving group, and polarity of the first unit is less than polarity of the second unit.

Quantum dot ligand, preparation method and quantum dot light-emitting device are provided. The quantum dot ligand has a structural general formula as shown in Formula I, XYZ Formula I; wherein X is a coordination group for forming a coordination bond with a quantum dot body; Z is a dissolving group, and the dissolving group is selected from a polar group; Y includes a linking group and a photosensitive group connected with each other, and the linking group is connected between the coordination group and the photosensitive group; the linking group is selected from an alkylene group; the photosensitive group is capable of undergoing bond breaking under light condition such that the quantum dot ligand decomposes into a first unit including the coordination group and the linking group, and a second unit including the dissolving group, and polarity of the first unit is less than polarity of the second unit.

Benzamide compounds and derivatives thereof, as can be used for selective inhibition of the SIRT2 enzyme and/or therapeutic use in the treatment of Huntington's disease.

Benzamide compounds and derivatives thereof, as can be used for selective inhibition of the SIRT2 enzyme and/or therapeutic use in the treatment of Huntington's disease.

The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

Benzamide compounds and derivatives thereof, as can be used for selective inhibition of the SIRT2 enzyme and/or therapeutic use in the treatment of Huntington's disease.

Benzamide compounds and derivatives thereof, as can be used for selective inhibition of the SIRT2 enzyme and/or therapeutic use in the treatment of Huntington's disease.

Benzamide compounds and derivatives thereof, as can be used for selective inhibition of the SIRT2 enzyme and/or therapeutic use in the treatment of Huntington's disease.